How do you assess the risk of developing demyelinating disease when initiating TNF inhibitors?

Demyelinating disease (DD) associated with TNF inhibitors is rare. Risk assessment is mostly clinical. TNF should be avoided if personal history of established DD specially MS. Strong family history in first degree relatives or concerning neurological symptoms should warrant caution as well; Given t...